CCM
NYSEConcord Medical Services Holdings Limited
Website
News25/Ratings0
News · 26 weeks9-83%
2025-10-262026-04-19
Mix790d
- Insider6(86%)
- SEC Filings1(14%)
Latest news
25 items- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- INSIDERSEC Form 3 filed by new insider Yang Jianyu3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)
- INSIDERSEC Form 3 filed by Concord Medical Services Holdings Limited3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)
- INSIDERSEC Form 3 filed by Concord Medical Services Holdings Limited3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)
- INSIDERSEC Form 3 filed by Concord Medical Services Holdings Limited3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)
- INSIDERSEC Form 3 filed by Concord Medical Services Holdings Limited3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)
- INSIDERSEC Form 3 filed by Concord Medical Services Holdings Limited3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- PRConcord Medical Schedules 2025 Annual Meeting of ShareholdersBEIJING, Dec. 2, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it will hold its 2025 annual general meeting of shareholders (the "Meeting") on December 29, 2025, at 10:00 a.m. (Beijing Time). The meeting will be held at Room 26A1-26A5, East Tower, Hanwei Building, No. 7 Guanghua Road, Chaoyang District, Beijing, China. The shareholder record date is December 19, 2025. A copy of the notice of Meeting is available on the Company's investor relations website at https://ir.ccm.cn. No proposal will be submitted
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- PRConcord Medical Reports Financial Results for the First Half of 2025BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1]. 2025 First Half Highlights Total net revenues were RMB200.6 million (US$28.0 million) in the first half of 2025, representing a 8.3% decrease from total net revenues of RMB218.8 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB153.0 million (US$21.4 million) and the net revenues from the network
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- PRConcord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant MelanomaBEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma. Choroidal malignant melanoma is a common intraocular malignancy. The traditional standard treatment is enucleation, i.e. eye removal. Although enucleation can effect
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- PRConcord Healthcare Announces Official Release of the Proton Therapy Large ModelBEIJING, May 29, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE:CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that Concord Healthcare had made important progress in precise tumor diagnosis and treatment technology. Concord Healthcare's self-developed large language model ("LLM") in the vertical field of proton therapy was officially released and successfully deployed in Guangzhou Concord Cancer Hospital. Since the commencement of the proton therapy in Guangzhou Concord Cancer Hospi
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)
- SECSEC Form 6-K filed by Concord Medical Services Holdings Limited6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)